Cargando…

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain

Purpose: The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C viral (HCV) infection. This study aims to establish real-world treatment efficacy of Sofosbuvir-based (SOF-B) and Ombitasvir/Paritaprevir/Ritonavir-based (OPR-B) regimens. Patients an...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulla, Maheeba, Ali, Hamed, Nass, Hafsa, Khamis, Jawad, AlQamish, Jehad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524762/
https://www.ncbi.nlm.nih.gov/pubmed/31191049
http://dx.doi.org/10.2147/HMER.S190967
_version_ 1783419608902926336
author Abdulla, Maheeba
Ali, Hamed
Nass, Hafsa
Khamis, Jawad
AlQamish, Jehad
author_facet Abdulla, Maheeba
Ali, Hamed
Nass, Hafsa
Khamis, Jawad
AlQamish, Jehad
author_sort Abdulla, Maheeba
collection PubMed
description Purpose: The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C viral (HCV) infection. This study aims to establish real-world treatment efficacy of Sofosbuvir-based (SOF-B) and Ombitasvir/Paritaprevir/Ritonavir-based (OPR-B) regimens. Patients and methods: This prospective, non-randomized observational real-life study was conducted in Salmaniya Medical Complex, Bahrain, and included consecutive patients with chronic HCV infection (genotypes 1–4) who were treated with direct-acting antivirals. Sustained virologic response to therapy was assessed at week 12 post end of treatment (SVR12). Results: Of the 167 patients included, 60.5% (n=101) were treated with SOF-B and 39.5% (n=66) with OPR-B regimens for 12 weeks (n=148; 88.6%) or 24 weeks (n=19; 11.4%). SVR12 was achieved in 156 (93.4%) patients, 4 patients failed to achieve SVR despite completion of treatment, and 7 patients discontinued treatment due to non-compliance and were included in the analysis on an intention-to-treat basis. There was no difference between SOF-B and OPR-B regimens (95/101; 94.1%) and (61/66; 92.4%), respectively (p=0.68). However, SVR12 rates were significantly higher in patients without liver cirrhosis (103/104; 99.0%) compared to patients with cirrhosis (53/63; 84.1%; p<0.001), and in patients who received 12-week-regimen (141/148; 95.3%) compared to those who received 24-week regimen (15/19; 78.9%; p<0.024). However, logistic regression analysis identified cirrhosis at baseline to be the only independent predictor of non-SVR12 (OR: 16.1, 95% confidence interval 1.96–131.91, p=0.01). Apart from Hb, INR, and ALP, all other laboratory parameter improved following treatment (p<0.05). Conclusion: Both SOF-B and OPR-B regimens achieved high SVR12 rates in this real-life cohort of patients with chronic HCV infection, similar to what is reported in other real-world studies. Cirrhosis was the only independent predictor of poor response.
format Online
Article
Text
id pubmed-6524762
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65247622019-06-12 Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain Abdulla, Maheeba Ali, Hamed Nass, Hafsa Khamis, Jawad AlQamish, Jehad Hepat Med Original Research Purpose: The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C viral (HCV) infection. This study aims to establish real-world treatment efficacy of Sofosbuvir-based (SOF-B) and Ombitasvir/Paritaprevir/Ritonavir-based (OPR-B) regimens. Patients and methods: This prospective, non-randomized observational real-life study was conducted in Salmaniya Medical Complex, Bahrain, and included consecutive patients with chronic HCV infection (genotypes 1–4) who were treated with direct-acting antivirals. Sustained virologic response to therapy was assessed at week 12 post end of treatment (SVR12). Results: Of the 167 patients included, 60.5% (n=101) were treated with SOF-B and 39.5% (n=66) with OPR-B regimens for 12 weeks (n=148; 88.6%) or 24 weeks (n=19; 11.4%). SVR12 was achieved in 156 (93.4%) patients, 4 patients failed to achieve SVR despite completion of treatment, and 7 patients discontinued treatment due to non-compliance and were included in the analysis on an intention-to-treat basis. There was no difference between SOF-B and OPR-B regimens (95/101; 94.1%) and (61/66; 92.4%), respectively (p=0.68). However, SVR12 rates were significantly higher in patients without liver cirrhosis (103/104; 99.0%) compared to patients with cirrhosis (53/63; 84.1%; p<0.001), and in patients who received 12-week-regimen (141/148; 95.3%) compared to those who received 24-week regimen (15/19; 78.9%; p<0.024). However, logistic regression analysis identified cirrhosis at baseline to be the only independent predictor of non-SVR12 (OR: 16.1, 95% confidence interval 1.96–131.91, p=0.01). Apart from Hb, INR, and ALP, all other laboratory parameter improved following treatment (p<0.05). Conclusion: Both SOF-B and OPR-B regimens achieved high SVR12 rates in this real-life cohort of patients with chronic HCV infection, similar to what is reported in other real-world studies. Cirrhosis was the only independent predictor of poor response. Dove 2019-05-13 /pmc/articles/PMC6524762/ /pubmed/31191049 http://dx.doi.org/10.2147/HMER.S190967 Text en © 2019 Abdulla et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Abdulla, Maheeba
Ali, Hamed
Nass, Hafsa
Khamis, Jawad
AlQamish, Jehad
Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
title Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
title_full Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
title_fullStr Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
title_full_unstemmed Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
title_short Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
title_sort efficacy of direct-acting antiviral therapy for hepatitis c viral infection. real-life experience in bahrain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524762/
https://www.ncbi.nlm.nih.gov/pubmed/31191049
http://dx.doi.org/10.2147/HMER.S190967
work_keys_str_mv AT abdullamaheeba efficacyofdirectactingantiviraltherapyforhepatitiscviralinfectionreallifeexperienceinbahrain
AT alihamed efficacyofdirectactingantiviraltherapyforhepatitiscviralinfectionreallifeexperienceinbahrain
AT nasshafsa efficacyofdirectactingantiviraltherapyforhepatitiscviralinfectionreallifeexperienceinbahrain
AT khamisjawad efficacyofdirectactingantiviraltherapyforhepatitiscviralinfectionreallifeexperienceinbahrain
AT alqamishjehad efficacyofdirectactingantiviraltherapyforhepatitiscviralinfectionreallifeexperienceinbahrain